AstraZeneca plc (NYSE:AZN) has materialized the agreement with Leo Pharma for the licensing of the dermatology molecule, tralokinumab. The latter has made a payment of $115 million to acquire the worldwide rights of the drug, which is indicated for the management and treatment of atopic dermatitis. The investigational drug has completed phase 2b trial in patients with skin inflammatory diseases. By virtue of the licensing agreement, AstraZeneca has the rights to acquire the commercial milestones as well as sale royalties.